Ivermectin reduces COVID death risk by 92%, peer-reviewed study finds
By Dr. Paul Craig Roberts: As I wrote not long after the “Covid pandemic” hype was underway, there were two known preventatives and cures: HCQ and Ivermectin. This known medical fact had to be suppressed by Fauci, Big Pharma, and their political allies. Otherwise in the presence of cures, the emergency use authorization of the untested and extremely dangerous Covid “vaccine” could not be granted.
As for unspecified reasons getting the entire world population “vaccinated” was the goal, the cures and the medical doctors and scientists who recommended them were suppressed.
Consequently, people all over the world are dropping dead daily and others are burdened with lifetime health injuries from the “vaccine.”
The Covid vaccination program is the worst crime ever inflicted on humanity. The people responsible should be arrested, tried, convicted and executed. Instead, they have made huge sums of money and awarded medals.
Hundreds of thousands of deaths in the US, and millions worldwide,
could have been prevented by using Ivermectin (as was done in Peru and
India).
Meanwhile, the AMA is taking away the licenses from physicians who prescribe Ivermectin and save lives.
https://www.theblaze.com/news/ivermectin-covid-treatment-new-study
Ivermectin reduces COVID death risk by 92%, peer-reviewed study finds
News
Paul Sacca
September 03, 2022
A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.
The large study was conducted by Flávio A. Cadegiani, MD, MSc, PhD.
Cadegiani is a board-certified endocrinologist with a master’s degree
and doctorate degree in clinical endocrinology.
The peer-reviewed study was published on Wednesday by the online medical
journal Cureus. The study was conducted on a strictly controlled
population of 88,012 people from the city of Itajaí in Brazil.
Individuals who used ivermectin as prophylaxis or took the medication
before being infected by COVID experienced significant reductions in
death and hospitalization.
According to the study, those who took ivermectin regularly had a 92%
reduction in their COVID death risk compared to non-users and 84% less
than irregular users.
“The hospitalization rate was reduced by 100% in regular users compared
to both irregular users and non-users,” the study stated.
The impressive reduction for regular ivermectin users was evident
despite the regular users being at a higher risk for COVID deaths. The
regular users were older and had a higher prevalence of type 2 diabetes
and hypertension than irregular and non-users.
Irregular users of ivermectin had a 37% lower mortality rate reduction than non-users.
The study defined regular users as those who used more than 30
tablets of ivermectin over five months. The dosage of ivermectin was
determined by body weight, but “most of the population used between two
and three tablets daily for two days, every 15 days.”
“Non-use of ivermectin was associated with a 12.5-fold increase in
mortality rate and a seven-fold increased risk of dying from COVID-19
compared to the regular use of ivermectin,” the study read. “This
dose-response efficacy reinforces the prophylactic effects of ivermectin
against COVID-19.”
Cadegiani believes the study showed a “dose-response effect” – which
means that increasing levels of ivermectin decreased the risk of
hospitalization and death from COVID-19.
Cadegiani wrote on Twitter, “An observational study with the size and
level of analysis as ours is hardly achieved and infeasible to be
conducted as a randomised clinical trial. Conclusions are hard to be
refuted. Data is data, regardless of your beliefs.”
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92%
Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results
of a Prospective Observational Study of a Strictly Controlled
Population of 88,012 Subjects
Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra,
Fernando Carlos Proença, Juan J. Chamie, Jennifer A. Hibberd, Pierre
Kory, Flavio A. Cadegiani
Published: August 31, 2022 (see history)
DOI: 10.7759/cureus.28624
Cite this article as: Kerr L, Baldi F, Lobo R, et al. (August 31, 2022)
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92%
Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results
of a Prospective Observational Study of a Strictly Controlled Population
of 88,012 Subjects. Cureus 14(8): e28624. doi:10.7759/cureus.28624
Abstract
Background
We have previously demonstrated that ivermectin used as prophylaxis for
coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a
strictly controlled citywide program in Southern Brazil (Itajaí,
Brazil), was associated with reductions in COVID-19 infection,
hospitalization, and mortality rates. In this study, our objective was
to determine if the regular use of ivermectin impacted the level of
protection from COVID-19 and related outcomes, reinforcing the efficacy
of ivermectin through the demonstration of a dose-response effect.
Methods
This exploratory analysis of a prospective observational study involved a
program that used ivermectin at a dose of 0.2 mg/kg/day for two
consecutive days, every 15 days, for 150 days. Regularity definitions
were as follows: regular users had 180 mg or more of ivermectin and
irregular users had up to 60 mg, in total, throughout the program.
Comparisons were made between non-users (subjects who did not use
ivermectin), and regular and irregular users after multivariate
adjustments. The full city database was used to calculate and compare
COVID-19 infection and the risk of dying from COVID-19. The COVID-19
database was used and propensity score matching (PSM) was employed for
hospitalization and mortality rates.
Results
Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years
old or up and were not infected by COVID-19 until July 7, 2020, from
which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin.
Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg)
and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548
participants were not included in the analysis. COVID-19 infection rate
was 49% lower for regular users (3.40%) than non-users (6.64%) (risk
rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than
irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001).
The infection rate was 32% lower for irregular users than non-users (RR:
0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants,
regular users were older and had a higher prevalence of type 2 diabetes
and hypertension than irregular and non-users. After PSM, the matched
analysis contained 283 subjects in each group of non-users and regular
users, between regular users and irregular users, and 1,542 subjects
between non-users and irregular users. The hospitalization rate was
reduced by 100% in regular users compared to both irregular users and
non-users (p < 0.0001), and by 29% among irregular users compared to
non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was
92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p
= 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI:
0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality
rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049).
Risk of dying from COVID-19 was 86% lower among regular users than
non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than
irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while
irregular users had a 51% reduction compared to non-users (RR: 0.49; 95%
CI: 0.32-0.76; p = 0.001).
Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in
mortality rate and a seven-fold increased risk of dying from COVID-19
compared to the regular use of ivermectin. This dose-response efficacy
reinforces the prophylactic effects of ivermectin against COVID-19.
No comments:
Post a Comment